

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: DHI-10857	Serial No.: 10/578,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: David R. Scholl	
		Filing or 371(c) Date: 05/03/2006	Group Art Unit: 1648

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Document / Patent Number	Publication / Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,244,946	13 Jan 1981	Rivier et al.	424	177	11 Jun 1979
	2	4,946,778	7 Aug 1990	Ladner et al.	435	69.6	19 Jan 1989
	3	5,134,127	28 Jul 1992	Stella et al.	514	58	23 Jan 1990
	4	5,270,163	14 Dec 1993	Gold et al.	435	6	17 Aug 1992
	5	5,376,645	27 Dec 1994	Stella et al.	514	58	27 Jul 1992
	6	5,545,806	13 Aug 1996	Lonberg et al.	800	2	16 Dec 1992
	7	5,569,825	29 Oct 1996	Lonberg et al.	800	2	17 Dec 1991
	8	5,625,126	29 Apr 1997	Lonberg et al.	800	2	7 Dec 1994
	9	5,760,029	2 Jun 1998	Jadhav et al.	514	211	13 Mar 1997
	10	6,252,043	26 Jun 2001	Hession et al.	530	350	22 Sep 1994
	11	6,376,172	23 Apr 2002	Scholl et al.	435	5	14 Sep 2000
	12	6,472,206	29 Oct 2002	Scholl et al.	435	325	28 Apr 2000
	13	6,610,474	26 Aug 2003	Huang	435	5	25 Apr 2002

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	14	WO 2004/101781	25 Nov 2004	WIPO				
	15	WO 2005/035712	21 Apr 2005	WIPO				
	16	EP 0 140 308	8 May 1985	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

17	Benbacer et al. (1997) "Interspecies aminopeptidase-N chimerase reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus," <i>J Virol</i> , 71:734-737
18	Blondelle et al. (1995) "Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities," <i>Trends Anal Chem</i> , 14:83-92
19	Chaloner-Larsson et al. "Establishment and maintenance of a persistent infection of L132 cells by human coronavirus strain 229E," (1981) <i>Arch Virol</i> , 69:117-129
20	Cole et al., (1985) "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," in <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc., pp 77-96
21	Compton et al. (1982) "Coronavirus species specificity: Murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein," <i>J Virol</i> , 66:7420-7428
22	Cote et al. (1983) "Generation of human monoclonal antibodies reactive with cellular antigens," <i>Proc Natl Acad Sci USA</i> , 80:2026-2030
23	de Kruij et al. (1996) "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," <i>FEBS Lett</i> , 399:232-236
24	Delmas et al. (1992) "Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV," <i>Nature</i> , 357:417-420
25	Ding et al. (1995) "Synthesis and biological activity of oligosaccharide libraries," <i>Adv Exp Med Biol</i> , 376:261-269
26	Drosten et al. (2003) "Identification of a novel coronavirus in patients with severe acute respiratory syndrome," <i>N Engl J Med</i> , 348:1967-1976
27	Dveksler et al. (1991) "Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV," <i>J Virol</i> , 65:6881-6891
28	Dveksler et al. (1995) "Mouse hepatitis virus receptor activities of an MHVR/mph chimera and MHVR mutants lacking N-linked glycosylation of the N-terminal domain," <i>J Virol</i> , 69:543-546
29	Dveksler et al. (1996) "Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster of human cells susceptible to MHV infection," <i>J Virol</i> , 70:4142-4145

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BE/

FORM PTO-1449 (Modified)	APR 30 2008	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: DHI-10857	Serial No.: 10/578,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Separate Sheets If Necessary) (37 CFR § 1.98(b))			Applicant: David R. Scholl	
			Filing or 371(c) Date: 05/03/2006	Group Art Unit: 1648

30	Ecker and Crook (1995) "Combinatorial drug discovery: Which methods will produce the greatest value?" <i>Bio/Technology</i> 13:351-360
31	Fields and Noble (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids," <i>Intl Peptide Protein Res</i> , 35:161-214
32	Fouchier <i>et al.</i> (2003) "Koch's postulates fulfilled for SARS virus," <i>Nature</i> , 423:240
33	Gleaves <i>et al.</i> (1992) "Detection of human cytomegalovirus in clinical specimens by centrifugation culture with a nonhuman cell line," <i>J Clin Microbiol</i> 30:1045-8
34	Gordon <i>et al.</i> (1994) "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions," <i>J Med Chem</i> , 37:1385-1401
35	Hambor <i>et al.</i> (1988) "Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone," <i>J Exp Med</i> , 168:1237-1245
36	Holmes and Lai (1996) "Coronaviridae: The Viruses and Their Replication," in <i>Fields Virology</i> , Third Edition, Lippincott-Raven, pp. 1075-1093
37	Holmes <i>et al.</i> (2001) "Coronaviruses," in <i>Fields Virology</i> , Fourth Edition, Lippincott Williams & Wilkins, Chapter 36, pp. 1187-1203
38	Huse <i>et al.</i> (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246:1275-1281
39	Karaoglu <i>et al.</i> (1995) "Functional characterization of Ost3p. Loss of the 34-kD subunit of the <i>Saccharomyces cerevisiae</i> oligosaccharyltransferase results in biased underglycosylation of acceptor substrates," <i>J Cell Biol</i> , 130:567-577
40	Köhler and Milstein (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-497
41	Koivunen <i>et al.</i> (1994) "Isolation of a highly specific ligand for the $\alpha_5\beta_1$ integrin from a phage display library," <i>J Cell Biol</i> , 124: 373-380
42	Kolb <i>et al.</i> (1997) "Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N," <i>J Gen Virol</i> , 78:2795-2802
43	Kontoyiannis <i>et al.</i> (2003) "Aminopeptidase N inhibitors and SARS," <i>Lancet</i> , 361:1558
44	Kozbor <i>et al.</i> (1983) "The production of monoclonal antibodies from human lymphocytes," <i>Immunol Today</i> , 4:72
45	Ksiazek <i>et al.</i> (2003) "A novel coronavirus associated with severe acute respiratory syndrome," <i>N Engl J Med</i> , 348:1953-1966
46	Kuiken <i>et al.</i> (2003) "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome," <i>Lancet</i> , 362:263-270
47	Liang <i>et al.</i> (1996) "Parallel synthesis and screening of a solid phase carbohydrate library," <i>Science</i> , 274:1520-1522
48	Look <i>et al.</i> (1989) "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," <i>J Clin Invest</i> , 83:1299-1307
49	Markus-Sekura (1988) "Techniques for using antisense oligodeoxyribonucleotides to study gene expression," <i>Anal Biochem</i> , 172:289-295
50	Marra <i>et al.</i> (2003) "The genome sequence of the SARS-associated coronavirus," <i>Science</i> , 300:1399-1404
51	Meienhofer, (1973) "Peptide synthesis: A review of the solid-phase method," in <i>Hormonal Proteins and Peptides</i> , Vol. II, Chapter 3, Academic Press (title and copyright pages only)
52	Murphy and Chanock, (2001) "Immunization against viral diseases" in <i>Fields Virology</i> , Fourth Edition, Knipe and Howley, Lippincott Williams & Wilkins, Chapter 16, pp. 435-467
53	Nakabayashi <i>et al.</i> (1982) "Growth of human hepatoma cell lines with differentiated function in chemically defined medium," <i>Cancer Res</i> , 42: 3858-3863
54	Nakabayashi <i>et al.</i> (1984) "Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium," <i>Gann</i> , 75: 151-158 (abstract only)
55	Nakabayashi <i>et al.</i> (1985) "Hormonal control of α -fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium," <i>Cancer Res</i> . 45:6379-6383
56	Palache <i>et al.</i> (1997) "Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs," <i>J Infect Dis</i> , 176(Suppl 1):S20-S23
57	Peiris <i>et al.</i> (2003) "Coronavirus as a possible cause of severe acute respiratory syndrome," <i>Lancet</i> , 361:1319-1325
58	Poon <i>et al.</i> (2003) "Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)," <i>Clin Chem</i> , 49:953-955
59	Poutanen <i>et al.</i> (2003) "Identification of severe acute respiratory syndrome in Canada," <i>N Engl J Med</i> , 348:1995-2005
60	Rota <i>et al.</i> (2003) "Characterization of a novel coronavirus associated with severe acute respiratory syndrome," <i>Science</i> , 300:1394-1399
61	Sawicki and Sawicki (1995) "Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands," <i>Adv Exp Med Biol</i> , 380:499-506
62	Sawicki and Sawicki (1998) "A new model for coronavirus transcription," <i>Adv Exp Biol</i> , 440:215-219

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BE/

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: DHI-10857	Serial No.: 10/578,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: David R. Scholl	
		Filing or 371(c) Date: 05/03/2006	Group Art Unit: 1648

Examiner: /Benjamin Blumel/ Date Considered: 07/09/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ~~EXAMINER'S CONSIDERATIONS EXCEPT WHERE LINED THROUGH~~

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /BB/